Autolus Therapeutics plcAUTLEarnings & Financial Report
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company specializing in the development of next-generation engineered chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of hematological malignancies and solid tumors. It operates in the global oncology biotech market, advancing a pipeline of targeted immunotherapy candidates across multiple clinical development stages.
Revenue
$20.9M
Gross Profit
$-3.5M
Operating Profit
$-61.2M
Net Profit
$-47.9M
Gross Margin
-16.8%
Operating Margin
-292.6%
Net Margin
-229.0%
YoY Growth
N/A
EPS
$-0.18
Autolus Therapeutics plc Q2 FY2025 Financial Summary
Autolus Therapeutics plc reported revenue of $20.9M for Q2 FY2025, with a net profit of $-47.9M (up 17.8% YoY) (-229.0% margin).
Key Financial Metrics
| Total Revenue | $20.9M |
|---|---|
| Net Profit | $-47.9M |
| Gross Margin | N/A |
| Operating Margin | -292.6% |
| Report Period | Q2 FY2025 |
Autolus Therapeutics plc Quarterly Revenue & Net Profit History
Autolus Therapeutics plc results over the last 6 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $21.2M | — | $-79.1M | -373.3% |
| Q2 FY2025 | $20.9M | — | $-47.9M | -229.0% |
| Q1 FY2025 | $9.0M | -11.0% | $-70.2M | -781.1% |
| Q3 FY2024 | $0 | — | $-82.1M | N/A |
| Q2 FY2024 | $0 | — | $-58.3M | N/A |
| Q1 FY2024 | $10.1M | — | $-52.7M | -522.1% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $10.1M | $0 | $0 | $9.0M | $20.9M | $21.2M |
| YoY Growth | N/A | N/A | N/A | -11.0% | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Assets | $901.4M | $853.6M | $827.5M | $746.3M | $721.0M | $661.9M |
| Liabilities | $319.4M | $325.8M | $350.5M | $375.2M | $374.5M | $396.5M |
| Equity | $582.0M | $527.8M | $477.0M | $371.1M | $346.5M | $265.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Operating CF | $-40.5M | $-51.1M | $-76.7M | $-75.6M | $-72.8M | $-67.9M |